Research using the most cutting-edge Magnetic Recsonance Imaging (MRI), confirms that pharmaceutical-grade chondroitin sulphate, (CSbBIOACTIVE), significantly reduces the effects of osteoarthritis on the knee.

Osteoarthritis, which affects 27 million Americans alone, is the most common type of arthritis. This condition causes stiffness, pain, and loss of movement. Cartilage acts as a shock-absorbing and friction reducer by providing a hard, rubbery layer on the joints. The cartilage becomes less elastic and loses its cushioning ability with osteoarthritis. This causes the bones to rub against one another. Cartilage degeneration can cause the joint to become less flexible and affect its shape. Additionally, bone marrow lesions (bruising) can form inside the bone which may cause knee pain.

Recently published trial results in a leading arthritis journal show that chondroitin Sulphate treatment significantly reduced cartilage losses and bone marrow lesion from osteoarthritis.

Chondroitin is a naturally occurring substance that keeps cartilage healthy. It absorbs fluid and provides building blocks to make new cartilage. Chondroitin could also block enzymes responsible for destroying cartilage.

Dr. Jean-Pierre Pelletier of the University of Montreal Hospital Research Centre, Canada was able to measure for the very first time the effects of chondroitin sulfate (chondroitin sulfate) on cartilage loss. Researchers were able measure and show significant improvements following treatment with chondroitin.

Patients with treatment showed significant cartilage loss after six months compared to patients who received placebo. The size of bone marrow tumors was significantly reduced by treatment 12 months later.

“Reducing bone marrow lesions may help lessen some of the pain associated with osteoarthritis,” said Dr. Pelletier. “From these results, we can conclude that chondroitin sulfate is a safe drug that significantly reduces the volume of cartilage loss and slows down the progression of osteoarthritis in the knee.”He noted that “Patients must be provided highly purified pharmaceutical-grade chondroitin sulphate, the one used in this study, as this is the only one that can guarantee such efficacy and specifically, safety results.”